The executive session is scheduled for 3:00 p.m. ET, providing a platform for the firm to detail its ongoing clinical strategy. Management will remain on-site throughout the three-day event to conduct private meetings with institutional investors, according to the company announcement released Wednesday.
In section Releases
Actinium Pharmaceuticals to Showcase Radiotherapy Pipeline in New York
Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, is set to address the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14. The presentation will highlight the company’s recent progress in developing targeted radiotherapies for solid tumors and hematologic malignancies.
Actinium currently manages a diverse portfolio, including the development of Iomab-B for bone marrow transplant conditioning and the Actimab-A program for acute myeloid leukemia. With a patent portfolio encompassing roughly 250 assets, the company aims to emphasize its proprietary work in cyclotron-based production of Ac-225 and its collaborative research efforts with the National Cancer Institute.
Comments (0)
No comments yet. Be the first!